THALES
3.11.2021 14:02:06 CET | Business Wire | Press release
In partnership with First Tech, global technology company Thales today announced it has helped venture capital-backed financial service provider SWAP launch its modern digital payment infrastructure. With Thales’s cloud-based payment transaction security solution, SWAP will deliver financial infrastructure technologies faster and more effectively to its banking-as-a-service customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005068/en/
Banking-as-a-Service
SWAP, a venture capital-backed financial service provider, was founded in 2018 to support fintech and service providers in the adoption of financial technology in response to demand across all sectors – from marketplaces to ride sharing – for more reliable transaction processing and expanded financial and payment services.
However, company expansion and customer satisfaction relied on in-built compliance with Payment Card Industry Data Standards (PCI DSS). As a start-up, SWAP wasn’t able to implement the entire technological infrastructure needed: a secure room would have slowed and complicated the launch process, and ultimately, SWAP needed to be able to provide accelerated, scalable, certified access to the market. First Tech and Thales’ solution grants SWAP the scalability and PCI certification it needs to grow as its customers do.
“Our solution, delivered collaboratively with First Tech, has proved instrumental in helping SWAP rapidly launch its product to market. SWAP’s lack of legacy systems meant that the team could leapfrog to providing the secure digital services their customers needed in a short amount of time, and this has translated to success for both SWAP and their customers. Thales has a rich heritage in being a trusted provider of solutions that protect the data and services businesses and end-users rely on. We look forward to continuing to support SWAP and its customers in their impressive growth,” said Todd Moore, VP Encryption Products at Thales.
Driving growth
First Tech’s hosted payShield Hardware Security Module (HSM) offers SWAP a cloud-based service with HSM off premises. Thales’ market-leading HSMs are highly scalable, providing the flexibility and agility needed to support SWAP in its future growth. The environment includes a secure room for insertion of keys, the support of trained professionals, team training, consultancy, and services.
Bruno Napolitano, CISO Security, Risk, and Fraud at SWAP explained, “Thales payShield 10K is considered the benchmark for payment HSMs, with an excellent performance and several global certifications that prove the reliability of the solution for PCI compliance. In fact, our credit card partner has confirmed this was the fastest implementation of card issuance they’ve undertaken in the past 15 years, which is testament to the solution at hand. This speed to market has already made a huge impact on our growth, and since launch, we’ve seen a four-fold increase in our customer portfolio. Looking ahead, we expect to accelerate our growth by 30% to 40% per year, always counting on the support from First Tech and Thales.”
Edmar Siqueira, Head of innovation, Digital Payments at First Tech added: “By working in tandem with Thales, we’ve been able to provide SWAP with a remote HSM management system which enables their business and their customers to benefit from operational cost savings, greater agility, and on-demand key management. Importantly, the success of this solution has been driven by both the strength of the product and the commitment from all parties to ensuring that the implementation process delivered a full-rounded understanding which will continue to serve SWAP well as it grows.
A bout Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Security
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005068/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
